Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Glioblastoma multiforme Clinical Trials

A listing of Glioblastoma multiforme medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (221) clinical trials

IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Glioblastoma

Non-invasive preoperative PET imaging evaluation and real-time fluorescence-guided surgery would be of great help in GBM patients. BBN, with the amino acid sequence of Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2, has been extensively used for the development of molecular probes for the imaging of gastrin-releasing peptide receptor (GRPR), a member of the G protein-coupled receptor ...

Phase N/A

Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme

There is pre-clinical data to suggest that neural progenitor cells in the subventricular zone may play a role in glioblastoma recurrence. Retrospective studies in humans suggest potentially improved survival in patients who received high doses of radiation to the subventricular zone when compared with patients who received lower radiation doses ...

Phase

Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma

PRIMARY OBJECTIVES: I. Measurement of tissue concentration of ixazomib (ixazomib citrate) in a glioblastoma after preoperative administration. II. Measurement of blood and plasma concentration of ixazomib during surgical sampling after preoperative administration. SECONDARY OBJECTIVES: I. Assessment of the safety of ixazomib after single dose administration in glioblastoma patients undergoing surgery ...

Phase N/A

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2

PAC-1 in combination with temozolomide (Component 2): after the MTD is established for single agent PAC-1 in Component 1, a modified-Fibonacci dose-escalation 3+3 design starts in Component 2, at a PAC-1 dose one level lower than the MTD of PAC-1 established in the single agent PAC-1 component (i.e., Component 1) ...

Phase

Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme

CAR T cell immunotherapy has achieved great success in CD19+ B-cell malignancies. Whether this new generation of cell-based immunotherapy can be applied to solid tumors remain to be investigated, partly due to hostile immune-suppressive tumor microenvironment which favors tumor growth but not immune system. Signaling pathway of programmed death 1 ...

Phase

Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine

Immunotherapy for Brain Tumors: Although it is usually ineffective alone, it has long been recognized that the immune system of tumor bearing hosts (human and animal models) does, indeed, mount an endogenous immune-mediated response to tumor. Unfortunately, this immune response alone is not sufficient in combating tumor. The balance of ...

Phase

Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Glioblastoma

Investigate the tolerance of Chlorogenic acid for injection in human body, determine the Maximum Tolerated Dose (MTD) and Dose-Limiting Toxicity (DLT) of Chlorogenic acid for injection in the advanced Glioblastoma Patients ; Determine the human pharmacokinetics characteristic of Chlorogenic acid for injection; Preliminary observation the effectiveness and effective dose; Provide ...

Phase

PD1-PIK Cell Therapy for Patients With Glioblastoma Multiforme

At present, the investigators constructed a transgenic modified T cells,namely pluripotent immune killer (PIK) cells, the cells can stablely express a high-level full-length PD1 antibody , transduce signals to activate T cells, which results in tumor killing. This pilot study is to determine the safety and efficacy of autologous T ...

Phase N/A

Low Dose Radiation Therapy for Glioblastoma Multiforme

In vitro and in vivo studies have suggested that low dose fractionated radiation therapy (LDFRT) may be used to potentiate full dose chemotherapy, decreasing the development of resistance found with standard doses of radiation and chemotherapy. This is a nonrandomized, open label, single institution phase II trial with a safety ...

Phase

Improving Goals of Care Discussion in Advanced Cancer Patients

Among advanced cancer patients, discussions about prognosis, goals of care (GoC) and end-of-life preferences improve quality of life of patients and reduce rates of hospital and ICU admission. Yet, few patients know their chemotherapy treatments will not cure their disease despite nearly all wishing to receive information- good & bad. ...

Phase N/A